SCHEMBL6367309

SCHEMBL6367309

CC(C)c1n[nH]c2c(=O)[nH]c(Cc3ccc(OCc4ccccc4)cc3)nc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE9A O76083 3/20 0.53
PDE1A P54750 3/20 0.53
PDE1B Q01064 3/20 0.53
PDE1C Q14123 3/20 0.53
PNP P00491 1/20 0.51
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CAPN1 P07384 1/20 0.44
PDE5A O76074 1/20 0.43
PTGES O14684 1/20 0.42
CCNK O75909 1/20 0.41
CCND3 P30281 1/20 0.41
GSK3B P49841 1/20 0.41
CDK7 P50613 1/20 0.41
CDK9 P50750 1/20 0.41
CCNH P51946 1/20 0.41
CDK6 Q00534 1/20 0.41
CDK12 Q9NYV4 1/20 0.41
DAO P14920 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6367469 0.90 PDE9A (0.52) PDE9APDE1APDE1BPDE1CPNP
SCHEMBL6366055 0.89 PDE9A (0.51) PDE9APDE1APDE1BPDE1CPNP
SCHEMBL6366064 0.89 GRIN1 (0.47) PDE9APDE1APDE1BPDE1CCAPN1
SCHEMBL6371061 0.86 RAB9A (0.51) PDE9APDE1APDE1BPDE1CPNP
SCHEMBL6370895 0.85 PLA2G2A (0.46) PDE9APDE1APDE1BPDE1CNPC1
SCHEMBL6367361 0.85 SMN1; SMN2 (0.46) PDE9APDE1APDE1BPDE1CL3MBTL1
SCHEMBL6367134 0.85 PDE9A (0.45) PDE9APDE1APDE1BPDE1CPNP
SCHEMBL6366904 0.83 PDE9A (0.50) PDE9APDE1APDE1BPDE1CCAPN1
SCHEMBL6366948 0.82 PDE9A (0.46) PDE9APDE1APDE1BPDE1CPNP
SCHEMBL6367359 0.82 PDE9A (0.50) PDE9APDE1APDE1BPDE1CNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6967204-B2 Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors PFIZER INC (US) 2005-11-22 US disclosed
US-20050070557-A1 Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors PFIZER INC 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070557-A1 Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors GPR119, PDE2A, PDE9A PDE9A 3/4885PDE1A 46/4885PDE1B 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.